CCR2 and neoplasm: Androgen blockade or AR loss increases CCL2 production from both tumor cells and stromal compartments, enhancing CCR2+ monocyte influx and downstream STAT signaling, which subsequently accelerates tumor progression and dissemination (15, 16).